Product image of Mulfinya (Fingolimod) supplied by GNH India

Mulfinya

Active Ingredient:
Fingolimod
Origin:
EU

Mulfinya (Fingolimod)

Fingolimod, the active ingredient in Mulfinya, is a sphingosine‑1‑phosphate receptor modulator presented as an oral tablet for oral use. It is indicated for the treatment of relapsing‑remitting multiple sclerosis in adult patients, helping to reduce the frequency of clinical relapses and to slow the accumulation of disability.

GNH India supplies Mulfinya as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels, ensuring quality and traceability for global markets.

Manufacturer / TM Owner

Mylan S.P.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mulfinya (fingolimod) is used in the management of multiple sclerosis, a chronic autoimmune disease of the central nervous system.

  • Relapsing‑remitting multiple sclerosis: reduces relapse frequency and slows disability progression.
  • Active secondary progressive multiple sclerosis: decreases disease activity in patients with superimposed relapses.
  • Clinically isolated syndrome at high risk of conversion: delays onset of clinically definite multiple sclerosis.

How It Works

  • Fingolimod selectively binds to sphingosine‑1‑phosphate (S1P) receptors on lymphocytes, causing internalization and functional antagonism of the receptor. This sequestration prevents lymphocytes from exiting lymph nodes, thereby reducing their presence in peripheral blood and diminishing autoimmune-mediated inflammation in the central nervous system.

Side Effects

Mulfinya may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Diarrhoea: usually transient.
  • Cough: non‑productive.
  • Fatigue: persistent tiredness.
  • Lymphopenia: reduced lymphocyte count.
  • Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects

  • Infections: opportunistic or severe bacterial infections.
  • Cardiac arrhythmia: bradycardia or atrioventricular block.
  • Macular oedema: visual disturbances requiring ophthalmic evaluation.
  • Severe liver injury: marked transaminase elevation or hepatitis.
  • Progressive multifocal leukoencephalopathy: rare viral CNS infection.

Precautions & Warnings

Before initiating Mulfinya, several safety considerations should be addressed.

  • Cardiac monitoring: obtain baseline ECG and observe heart rate during first dose.
  • Infection screening: assess for active infections and vaccinate appropriately before treatment.
  • Liver function: evaluate baseline hepatic enzymes and monitor periodically.
  • Ophthalmic assessment: perform baseline eye exam and repeat if visual symptoms occur.
  • Pregnancy contraindication: avoid use in pregnant women; ensure effective contraception.
  • Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Avoid Interactions

Mulfinya can interact with other medicines, requiring careful management. Major Interactions (Avoid):\n- CYP4F2 inhibitors: may increase fingolimod exposure.

  • Strong immunosuppressants: heightened risk of infections.
  • Live vaccines: contraindicated due to immunosuppression.

Moderate Interactions (Monitor Closely)

  • Antihypertensives: potential additive blood pressure effects.
  • Antiplatelet agents: increased bleeding tendency.
  • CYP3A4 inducers: may reduce fingolimod plasma levels.

Frequently Asked Questions

Mulfinya contains fingolimod and is prescribed for the treatment of relapsing‑remitting multiple sclerosis in adult patients. It helps to lower the number of disease relapses and to slow the progression of disability associated with the condition.

Fingolimod acts as a selective modulator of sphingosine‑1‑phosphate receptors on lymphocytes. By binding these receptors, it traps lymphocytes within lymph nodes, reducing their circulation in the bloodstream and limiting the autoimmune attack on the central nervous system.

The dosage of Mulfinya is determined by the prescribing physician based on the patient’s clinical condition, laboratory results, and overall health status. The prescriber will select the appropriate strength and dosing schedule for each individual.

Mulfinya is classified as pregnancy category X, indicating it should not be used during pregnancy because of potential fetal harm. It is also not recommended while breastfeeding, as the drug may be excreted in breast milk and affect the infant.

To request Mulfinya, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mulfinya belongs to the sphingosine‑1‑phosphate receptor modulator class, offering oral administration unlike many injectable disease‑modifying therapies. It provides a convenient dosing option and a distinct mechanism of action compared with interferons or monoclonal antibodies, though safety profiles and efficacy may differ among patients.

Mulfinya tablets should be stored at ambient temperature, below 25 °C, in the original blister pack. Keep the medication away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Mulfinya is taken orally as a tablet, usually once daily, with or without food. The exact timing and any special instructions are provided by the prescribing clinician and should be followed precisely.

Serious risks include severe infections, cardiac arrhythmias such as bradycardia, macular oedema affecting vision, significant liver injury, and rare opportunistic infections like progressive multifocal leukoencephalopathy. Patients should be monitored regularly for these potential complications.

Mulfinya is contraindicated in patients with a known hypersensitivity to fingolimod, those with active infections, recent cardiac events, uncontrolled hypertension, severe liver disease, or in women who are pregnant. It should also be avoided in individuals receiving live vaccines.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fingolimod

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT